The Differential Contribution of the Innate Immune System to a Good Pathological Response in the Breast and Axillary Lymph Nodes Induced by Neoadjuvant Chemotherapy in Women with Large and Locally Advanced Breast Cancers
Table 10
Clinical and pathological parameters of patients () studied and the Association of pre-NAC tumour-infiltrating CD163+ macrophages (TIMs) and pathological complete response (PCR).
Groups
TIMs
PCR
Low infiltration (n)
High infiltration (n)
Pearson chi-square value
value
Non-PCR (n)
PCR (n)
Pearson chi-square value
value
Age (years)
<50
6
8
0.002
0.966
8
6
0.308
0.579
≥50
8
11
9
10
BMI (kg/m2)
≤30
10
10
1.193
0.275
11
9
0.247
0.619
>30
4
9
6
7
Menopausal status
Pre
5
11
1.588
0.208
8
8
0.029
0.866
Post
9
8
9
8
Tumour size
<40 mm
8
10
0.066
0.797
9
9
0.036
0.849
≥40 mm
6
9
8
7
Nodal status
Negative
5
5
0.337
0.561
5
5
0.013
0.909
Positive
9
14
12
11
Tumour grade
1 (low)
1
1
11.270
0.004
2
0
9.303
0.010
2 (moderate)
10
3
10
3
3 (high)
3
15
5
13
Oestrogen receptor
Negative
2
9
3.970
0.046
3
8
3.882
0.049
Positive
12
10
14
8
HER-2 receptor
Negative
10
13
0.035
0.853
13
10
0.762
0.383
Positive
4
6
4
6
NAC regimen
AC-TX
6
10
0.308
0.579
6
10
2.443
0.118
AC-T
8
9
11
6
Recurrent disease(4)
No
8
14
0.992
0.319
7
15
10.252
0.001
Yes
6
5
10
1
Death(4)
No
11
16
0.172
0.678
12
15
2.972
0.085
Yes
3
3
5
1
NAC: neoadjuvant chemotherapy; BMI: body mass index (≤30: nonobese, >30: obese); AC-TX: doxorubicin, cyclophosphamide, taxotere, and xeloda® (capecitabine), respectively; (4)4-year follow-up; statistically significant.
